NASDAQ:NEUP Neuphoria Therapeutics (NEUP) Stock Price, News & Analysis $2.55 -0.03 (-1.16%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$2.57 +0.02 (+0.78%) As of 11/13/2026 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Neuphoria Therapeutics Stock (NASDAQ:NEUP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Neuphoria Therapeutics alerts:Sign Up Key Stats Today's Range$2.49▼$2.6450-Day Range$2.55▼$3.8052-Week Range$2.49▼$5.53Volume14,972 shsAverage Volume36,892 shsMarket Capitalization$13.80 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingReduce Company Overview Neuphoria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing investigational treatments for neurological and psychiatric conditions. The company’s work centers on advancing drug candidates intended to address needs in brain health. Its products remain in development rather than being established, marketed therapies. Publicly available information about Neuphoria’s specific development programs, operating geographies and leadership is limited, so no additional details are included here.AI Generated. May Contain Errors. Read More Neuphoria Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreNEUP MarketRank™: 1.950419727175 of 5 starsNeuphoria Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 688th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingReduce Consensus RatingNeuphoria Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialNeuphoria Therapeutics has a consensus price target of $7.00, representing about 174.5% upside from its current price of $2.55.Amount of Analyst CoverageNeuphoria Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Neuphoria Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Neuphoria Therapeutics are expected to decrease in the coming year, from ($2.43) to ($2.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neuphoria Therapeutics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neuphoria Therapeutics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuphoria Therapeutics has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.23% of the float of Neuphoria Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeuphoria Therapeutics has a short interest ratio ("days to cover") of 0.33, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neuphoria Therapeutics has recently increased by 92.52%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeuphoria Therapeutics does not currently pay a dividend.Dividend GrowthNeuphoria Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.39 News SentimentNeuphoria Therapeutics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Neuphoria Therapeutics this week, compared to 1 article on an average week. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Neuphoria Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders1.55% of the stock of Neuphoria Therapeutics is held by insiders.Percentage Held by Institutions15.90% of the stock of Neuphoria Therapeutics is held by institutions.Read more about Neuphoria Therapeutics' insider trading history. Receive NEUP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuphoria Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NEUP Stock News HeadlinesNeuphoria Therapeutics Inc. enters into Amendment No. 1 to rights agreement to extend expiration date to October 27, 2027October 23, 2026 | msn.comNeuphoria Therapeutics Inc. Reports Earnings Results for the Full Year Ended June 30, 2026September 19, 2026 | marketscreener.comMWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 15 at 1:00 AM | Base Camp Trading (Ad)Neuphoria Therapeutics Inc Ordinary Shares NEUPAugust 14, 2026 | morningstar.comMNeuphoria Therapeutics Inc (NEUP)August 8, 2026 | investing.comThe M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—NRIM, NEUP, SAFT, and RMAXJuly 30, 2026 | globenewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—PBCO, NEUP, SAFT, and PFLCJuly 28, 2026 | globenewswire.comNEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its ShareholdersJuly 24, 2026 | businesswire.comSee More Headlines NEUP Stock Analysis - Frequently Asked Questions How have NEUP shares performed this year? Neuphoria Therapeutics' stock was trading at $3.88 at the start of the year. Since then, NEUP stock has decreased by 34.3% and is now trading at $2.55. How were Neuphoria Therapeutics' earnings last quarter? Neuphoria Therapeutics Inc. (NASDAQ:NEUP) released its earnings results on Friday, May, 15th. The company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.47. How do I buy shares of Neuphoria Therapeutics? Shares of NEUP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today11/15/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 NEUP's financial health is in the Red zone, according to TradeSmith. NEUP has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NEUP Previous SymbolNASDAQ:NEUP CIK1191070 Webwww.neuphoriatx.com Phone(781) 439-5551FaxN/AEmployees1Year FoundedN/APrice Target and Rating Average Price Target for Neuphoria Therapeutics$7.00 High Price Target$7.00 Low Price Target$7.00 Potential Upside/Downside+174.5%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($6.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.45 million Net MarginsN/A Pretax Margin-1,157.67% Return on Equity-38.31% Return on Assets-28.92% Debt Debt-to-Equity RatioN/A Current Ratio27.83 Quick Ratio27.83 Sales & Book Value Annual Sales$1.17 million Price / Sales11.79 Cash FlowN/A Price / Cash FlowN/A Book Value$4.55 per share Price / Book0.56Miscellaneous Outstanding Shares5,410,000Free Float5,327,000Market Cap$13.80 million OptionableN/A Beta0.77 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:NEUP) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuphoria Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuphoria Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NEUP Stock Alerts